Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - October 2014


COPD: Novel Therapeutics and Management

20 Oct 2014 - 21 Oct 2014 - London, UK



Bookmark and Share


SMi is proud to present its 6th annual conference on COPD taking place from the 20th - 21st October 2014 in Central London. 

With the global COPD market forecasted to reach a value of $15.6 billion by 2019, COPD 2014 comes at a perfect time to provide the industry with a niche platform for discussion and a forum to learn from key visionaries in the field of COPD. 

The latest instalment in the successful series has evolved to include topical and current sessions, such as Patient Care and The Future of COPD, as well as presenting attendees with in-depth information on exacerbation and comorbidities, ensuring a successful clinical trial design and challenges in drug development and market access. 

“Fast and cost effective development of drugs that help to improve significantly the quality of life of patients requires the intensified collaboration of industry, academia, clinical research and regulators agencies. Working in the field of biomarkers at the interface of pre-clinical and clinical research makes this an everyday requirement. The 6th COPD conference will bring together key opinion leaders from different stakeholders and will therefore foster this collaboration, especially by providing a very focused agenda.” Thomas Schlange, Senior Biomarker Expert, Bayer

KEY SPEAKERS INCLUDE:

  • Marcello Milano, Executive Global Regulatory Affairs, Chiesi
  • Thomas Schlange, Senior Biomarker Expert, Bayer
  • Mercedes Prior, Head of Global Market Access, Almirall
  • Carla Bauer, Investigator, Novartis
  • Jan-Anders Karlsson, CEO, Verona Pharma
  • Ewan Walters, Medical Director, Teva
  • Rosa Lamarca, Head of Clinical Statistics, Almirall
  • Robert Wilson, Consultant Physician Lung Division, Royal Brompton Hospital
  • Abebaw Yohannes, Reader in Physiotherapy, Manchester Metropolitan University
  • Jim & Mary Nelson, Patient, Caregiver, Representatives of COPD Foundation and EFFORTS Online Support Group

WHY ATTEND THIS EVENT:

  • Understand the regulatory aspects of COPD, both from regulatory bodies and the industry
  • Examine the current challenges to modelling exacerbations in COPD using animal models
  • Evaluate COPD and comorbidities
  • Understand the link between COPD and anxiety and depression
  • Review the challenges in clinical trial designs and in drug development
  • Discover the importance of putting the patient at the centre of everything
  • Gain insight from real life story of a lung transplant patient

To register or to download a brochure, visit http://www.smi-online.co.uk/goto/2014copd-conference37.asp

Alternatively contact Fateja Begum on +44 (0) 207 827 6184 or email fbegum@smi-online.co.uk 



Further information
Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!